CKBA Cream, a subsidiary of the holding company, has been approved for clinical trials for rosacea.
October 2, 2025
Source: drugdu
86
Taienkang announced that its controlling subsidiary, Broad Venture Park, has received a "Notice of Approval for Drug Clinical Trial" from the National Medical Products Administration (NMPA), authorizing the conduct of a Phase II/III seamless adaptive clinical trial of CKBA Cream for the rosacea indication. CKBA Cream is a topical preparation independently developed by Broad Venture Park and is a Category 1 innovative chemical drug. To date, no Category 1 innovative drug for the treatment of rosacea has been approved for marketing in China .
Tainkang's innovative drug has been approved for clinical trials and is expected to fill the treatment gap for rosacea indications in China . If clinical trials can prove its efficacy, the market potential is considerable.
Source：https://www.stcn.com/article/detail/3358450.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
